RAPPORT THERAPEUTICS INC

CEO Ceesay Abraham sells 18,921 Rapport Therapeutics shares at $49.57, signaling disciplined insider strategy as the stock hits a $51.38 52‑week high.

Rapport Therapeutics insider sells 404 shares under a Rule 144 plan at $49.90—steady liquidity moves amid executive selling and CNS pipeline updates.

CEO Ceesay Abraham’s latest $300k sell‑off of 10k+ Rapport Therapeutics shares—timed amid a 7% price rebound and media buzz—signals strategic portfolio rebalancing, not panic.

Rapport Therapeutics insider buying spree: CDO Krishnaswamy’s 120k stock‑option purchase signals confidence in Phase III data and could boost or dilute the stock.

Insider buying at Rapport Therapeutics signals confidence in its CNS pipeline, spotlighting future Phase II data as a potential catalyst for upside.

Insider selling at Rapport Therapeutics shows a disciplined, pre‑planned approach, not panic, and highlights the company’s Phase 3 pipeline potential.